Roivant is a biopharmaceutical platform engineered to accelerate the development of innovative therapies. By organizing research into specialized, autonomous subsidiaries—the Vants—the company bridges the gap between massive, centralized infrastructure and the focused, entrepreneurial agility required for rapid drug discovery and commercialization.

 

(Done in collaboration with Applied Arts)

The biopharmaceutical industry is structurally bogged down by monolithic, risk-averse R&D processes. This institutional inertia prevents promising medicine from reaching the market efficiently. Roivant possessed the operational model to resolve this, but their brand was failing to communicate its role as an intellectual catalyst, often appearing as a disorganized conglomerate rather than a unified engine of discovery.

We stripped away the complex, heavy aesthetics typical of legacy pharma. We engineered a visual and verbal system that prioritizes structural modularity. By developing a cohesive identity that allows for individual subsidiary expression while maintaining a strong, singular corporate anchor, we transformed the brand from a collection of parts into a scalable, intellectual framework.

We architected a brand that functions as a high-performance laboratory for therapeutic development. By aligning the identity with the logic of decentralized agility, we transformed Roivant from a biotech holding company into a definitive architect of modern drug development. The result is a brand that feels precise—a sharp, reliable response to the demand for accelerated patient outcomes.